XML 36 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Information
 3 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Segment Information
11. Segment Information
Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.
Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products.
Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.
Revenue
The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:
Three Months Ended September 30,
(in millions)20202019
Pharmaceutical Distribution and Specialty Solutions (1) (2)$34,916 $33,212 
Nuclear and Precision Health Solutions196 216 
Pharmaceutical segment revenue
35,112 33,428 
Medical distribution and products (3)3,438 3,446 
Cardinal Health at-Home Solutions519 471 
Medical segment revenue
3,957 3,917 
  Total segment revenue39,069 37,345 
Corporate (4)(4)(4)
Total revenue$39,065 $37,341 
(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services".
(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.
(3)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.
(4)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
The following table presents revenue by geographic area:
Three Months Ended September 30,
(in millions)20202019
United States$37,976 $36,310 
International1,093 1,035 
  Total segment revenue39,069 37,345 
Corporate (1)(4)(4)
Total revenue$39,065 $37,341 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit
We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.
We do not allocate the following items to our segments: last-in
first-out, or ("LIFO"), inventory charges/(credits); surgical gown recall costs; restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; state opioid assessment related to prior fiscal years; other (income)/expense, net; interest expense, net; loss on early extinguishment of debt; and provision for income taxes.
In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $5 million and $3 million for the three months ended September 30, 2020 and 2019, respectively.
In connection with the opioid litigation as discussed further in Note 5, we recognized pre-tax charges of $1.02 billion and $5.63 billion during the three months ended September 30, 2020 and 2019, respectively, which was retained at Corporate.
The following table presents segment profit by reportable segment and Corporate:
Three Months Ended September 30,
(in millions)20202019
Pharmaceutical$402 $398 
Medical230 170 
Total segment profit632 568 
Corporate(1,256)(5,832)
Total operating loss$(624)$(5,264)
The following table presents total assets for each reportable segment and Corporate at:
(in millions)September 30, 2020June 30, 2020
Pharmaceutical$22,809 $22,398 
Medical14,985 14,691 
Corporate3,933 3,677 
Total assets$41,727 $40,766